1. Key Data on Improving Outcomes in HF Patients

2. 2016 ESC HF Guidelines

3. Maximize RAAS Inhibitor Dose to Achieve Greatest Benefit

4. 2016 ESC HF Guidelines (cont)

5. Definitions of HF: LVEF Criteria

6. HF Outcomes

7. Sacubitril/Valsartan, an ARNI, Mechanism of Action

8. ACE Inhibitor vs ARNI

9. PARADIGM-HF Study Design

10. Benefit of ARNI in HFrEF: Results of the PARADIGM-HF Trial

11. Benefit of ARNI in HFrEF: Results of the PARADIGM-HF Trial (cont)

12. Evidence-Based Guidelines: Use of Sacubitril/Valsartan

13. Dual Blockade of the RAAS

14. Sacubitril/Valsartan in HFrEF: Patient Monitoring

15. Sacubitril/Valsartan in HFrEF: Starting Dose and Dose Titration

16. Ivabradine Mechanism of Action

17. SHIFT Trial: Study Methods

18. SHIFT Trial: Treatment at Randomization

19. SHIFT: Ivabradine vs Placebo in Patients With Chronic HF

20. SHIFT: Overall Safety and Tolerability

21. Use of Ivabradine in Patients With HF and AF

22. SHIFT: Select AEs

23. Effects of Ivabradine on LV Remodeling and Function: SHIFT Echocardiography Substudy

24. Ivabradine and HRQoL: Results From the SHIFT Study

25. Trials With Sacubitril/Valsartan in Patients Following An Episode of ADHF

26. PIONEER-HF: Study Methods

27. PIONEER-HF: Change in NT-proBNP Concentration Over Time (Primary Endpoint)

28. PIONEER-HF: Additional Outcomes

29. TRANSITION: Study Design

30. TRANSITION: Important Observations

31. Use of Sacubitril/Valsartan: 2019 ESC Clinical Practice Update

32. Are Revisions to the Guidelines Regarding Sacubitril/Valsartan Use Warranted?

33. ARNI Use in Patients With HFrEF: Things To Consider

34. Hospitalization for Acute HF

35. Pre-Discharge Initiation of Ivabradine Following an Episode of ADHF?

36. Program Summary

37. Abbreviations

38. Abbreviations (cont)

39. Abbreviations (cont)